Je-Kyung Kim1, Jae-Yub Jung1, Heon Kim2, Sang-Yong Eom2, Youn-Soo Hahn1. 1. Department of Pediatrics, Chungbuk National University, Cheongju, Republic of Korea. 2. Department of Preventive Medicine, College of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, Republic of Korea.
Abstract
BACKGROUND AND OBJECTIVE: Recognition of patients at risk of asthma exacerbation is important for future asthma care and improved outcome. The aim of the present study was to see whether measurements of bronchodilator response (BDR) and fractional exhaled nitric oxide (FeNO) in combination provide prognostic information superior to either measurement alone in children with atopic asthma. METHODS: A total of 201 atopic children aged 8-16 years with intermittent or mild persistent asthma were included. Pulmonary function tests including BDR and FeNO were serially monitored 10 times or more over 2 years when subjects were not receiving controller medications. After completion of monitoring, 1-year observation for a loss of asthma control was performed. RESULTS: During the monitoring period, positive BDRs (≥12% in forced expiratory volume in 1 s (FEV1 ) from pre-bronchodilator value) and FeNO higher than 35 parts per billion (ppb) were observed at least once in 59% and 77% of participants. When analysed as continuous variables, both BDR (hazard ratio (HR): 1.21; 95% CI: 1.04-1.41; P = 0.014) and FeNO (HR: 1.27; 95% CI: 1.09-1.49; P = 0.003) were associated with increased risks for a control loss. Compared with patients showing either positive BDRs (HR: 3.19; 95% CI: 1.05-9.64) or FeNO higher than 35 ppb (HR: 4.70; 95% CI: 1.68-13.11), patients with both findings (HR: 7.08; 95% CI: 2.57-19.49) had greater risks for a control loss. CONCLUSION: These data support that combined use of BDR and FeNO measurements can modify predictive risk obtained from either measurement alone.
BACKGROUND AND OBJECTIVE: Recognition of patients at risk of asthma exacerbation is important for future asthma care and improved outcome. The aim of the present study was to see whether measurements of bronchodilator response (BDR) and fractional exhaled nitric oxide (FeNO) in combination provide prognostic information superior to either measurement alone in children with atopic asthma. METHODS: A total of 201 atopic children aged 8-16 years with intermittent or mild persistent asthma were included. Pulmonary function tests including BDR and FeNO were serially monitored 10 times or more over 2 years when subjects were not receiving controller medications. After completion of monitoring, 1-year observation for a loss of asthma control was performed. RESULTS: During the monitoring period, positive BDRs (≥12% in forced expiratory volume in 1 s (FEV1 ) from pre-bronchodilator value) and FeNO higher than 35 parts per billion (ppb) were observed at least once in 59% and 77% of participants. When analysed as continuous variables, both BDR (hazard ratio (HR): 1.21; 95% CI: 1.04-1.41; P = 0.014) and FeNO (HR: 1.27; 95% CI: 1.09-1.49; P = 0.003) were associated with increased risks for a control loss. Compared with patients showing either positive BDRs (HR: 3.19; 95% CI: 1.05-9.64) or FeNO higher than 35 ppb (HR: 4.70; 95% CI: 1.68-13.11), patients with both findings (HR: 7.08; 95% CI: 2.57-19.49) had greater risks for a control loss. CONCLUSION: These data support that combined use of BDR and FeNO measurements can modify predictive risk obtained from either measurement alone.
Authors: Andrea M Coverstone; Leonard B Bacharier; Bradley S Wilson; Anne M Fitzpatrick; William Gerald Teague; Wanda Phipatanakul; Sally E Wenzel; Benjamin M Gaston; Eugene R Bleecker; Wendy C Moore; Sima Ramratnam; Nizar N Jarjour; Ngoc P Ly; John V Fahy; David T Mauger; Kenneth B Schechtman; Huiqing Yin-DeClue; Jonathan S Boomer; Mario Castro Journal: Pediatr Pulmonol Date: 2019-08-19
Authors: Alice M Cottee; Leigh M Seccombe; Cindy Thamrin; Gregory G King; Matthew J Peters; Claude S Farah Journal: Chest Date: 2020-01-23 Impact factor: 9.410
Authors: Peter G Shields; Micah Berman; Theodore M Brasky; Jo L Freudenheim; Ewy Mathe; Joseph P McElroy; Min-Ae Song; Mark D Wewers Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-06-22 Impact factor: 4.254